Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/03/06 20:13:19」(JST)

Carumonam (INN) is a monobactam antibiotic.^[1]

References

^ McNulty, C. A.; Garden, G. M.; Ashby, J.; Wise, R. (1985). "Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam". Antimicrobial agents and chemotherapy 28 (3): 425–427. PMC 180266. PMID 4073864. //www.ncbi.nlm.nih.gov/pmc/articles/PMC180266/. edit

This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.

Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.

Bulitta JB1, Duffull SB, Landersdorfer CB, Kinzig M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F.
Diagnostic microbiology and infectious disease.Diagn Microbiol Infect Dis.2009 Oct;65(2):130-41. doi: 10.1016/j.diagmicrobio.2009.06.018.
Our objectives were to compare the pharmacokinetics (PK) of carumonam, a monobactam, between cystic fibrosis (CF) patients and healthy volunteers and assess its pharmacodynamic profile. We studied 10 adult CF patients and 18 healthy volunteers of similar body size (dose: 2.166 g of carumonam as 15-m
PMID 19748423

Potency of IMP-10 metallo-beta-lactamase in hydrolysing various antipseudomonal beta-lactams.

Zhao WH1, Hu ZQ, Shimamura T.
Journal of medical microbiology.J Med Microbiol.2008 Aug;57(Pt 8):974-9. doi: 10.1099/jmm.0.2008/001388-0.
Limited beta-lactams show antipseudomonal activity. The rapid spread of IMP-type metallo-beta-lactamases (MBLs), which have a broad spectrum of substrates and a poor susceptibility to clinically available inhibitors, further restricts beta-lactam use. In the present study, we evaluated the potency o
PMID 18628498

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility].

Kumamoto Y1, Tsukamoto T, Matsukawa M, Kunishima Y, Hirose T, Shigeta S, Yamaguchi O, Ishibashi K, Suzutani T, Yoshida H, Imafuku Y, Murai M, Watanabe K, Kobayashi Y, Uchida H, Matsuda S, Sato S, Fujime M, Fujita K, Igari J, Oguri T, Yamaguchi K, Furuya N, Deguchi T, Ishihara S, Ooe H, Oka T, Kitamura M, Fukuhara Y, Kamidono S, Arakawa S, Kumon H, Monden K, Matsumoto T, Muratani T, Naito S, Egashira T, Konishi T, Kohno S, Hirakata Y, Kondo A, Matsuda J, Nakano M.
The Japanese journal of antibiotics.Jpn J Antibiot.2006 Aug;59(4):217-315.
The bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa) isolated from patients diagnosed as urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2004 and July 2005. The susceptibilities of these ba
PMID 17111595

メチシリン耐性Staphylococcus aureusとPseudomonas aeruginosaの実験的混合感染に対するvancomycinとcefsulodin またはcarumonamとの併用効果

リンク元	「カルモナム」
拡張検索	「carumonam sodium」

Carumonam
Systematic (IUPAC) name
	2-[[1-(2-Amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	87638-04-8
ATC code	J01DF02
PubChem	CID 6857983
ChemSpider	5257278
UNII	486890PI06
ChEMBL	CHEMBL1256767
Chemical data
Formula	C12H14N6O10S2
Mol. mass	466.40 g/mol
	InChI InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7+/t5-,8+/m1/s1 ; Key:UIMOJFJSJSIGLV-PDWQJGMQSA-N ;
(what is this?) (verify);